v2.4.0.6

Consolidated Balance Sheets (USD $)	Mar. 31, 2012	Dec. 31, 2011
Current assets
Cash and cash equivalents	$ 80,621,646	$ 70,783,230
Accounts receivable, net	2,666,713	5,576,368
Advance to suppliers and other receivables	4,178,790	4,426,613
Inventory	266,324	1,024,467
Deferred tax asset		37,192
Total current assets	87,733,473	81,847,870
Non-current assets
Property and equipment, net	23,807,813	24,208,825
Construction in progress	873,806	872,891
Intangible assets	16,206,200	16,263,238
Total non-current assets	40,887,819	41,344,954
Total Assets	128,621,292	123,192,824
Current liabilities
Accounts payable	22,412	392,014
Taxes payable	5,676,260	6,433,014
Accrued expenses and other payables	665,019	739,797
Total current liabilities	6,363,691	7,564,825
Contingencies
Deferred Tax Liability, net	3,447,210	3,528,521
Total Liabilities	9,810,901	11,093,346
Stockholders' Equity
Common stock, $0.00001 par value; 100,000,000 shares authorized; 34,451,880 shares issued and outstanding at March 31, 2012 and December 31, 2011, respectively	344	344
Additional paid in capital	28,660,289	28,660,289
Statutory reserves	2,431,927	2,431,927
Accumulated other comprehensive income	7,063,473	6,932,246
Retained earnings	80,654,358	74,074,672
Total stockholders' equity	118,810,391	112,099,478
Total Liabilities and Stockholders' Equity	$ 128,621,292	$ 123,192,824

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

WEIKANG BIO-TECHNOLOGY GROUP CO., INC. 10-Q